Literature DB >> 11456376

Radiological imaging for the diagnosis of bone metastases.

L D Rybak1, D I Rosenthal.   

Abstract

Primary neoplasms of the skeleton are rare, but metastatic involvement is, unfortunately, a common occurrence. This is particularly true for certain primary tumors. Skeletal metastases are clinically significant because of associated symptoms, complications such as pathological fracture and their profound significance for staging, treatment and prognosis. Detection of bone metastases is, thus, an important part of treatment planning. The frequency with which metastases are detected varies considerably with the type of primary tumor and with the methodology utilized for detection. Four main modalities are utilized clinically: plain film radiography, CT scan, nuclear imaging and magnetic resonance imaging. In this discussion, we will review literature on the radiology of skeletal metastases with respect to lesion detection, assessment of response to treatment and possible therapeutic implications. The bulk of the discussion will focus on MRI and nuclear studies since most of the recent advances have been made in these areas.

Entities:  

Mesh:

Year:  2001        PMID: 11456376

Source DB:  PubMed          Journal:  Q J Nucl Med        ISSN: 1125-0135


  60 in total

1.  The improved accuracy of planar bone scintigraphy by adding single photon emission computed tomography (SPECT-CT) to detect skeletal metastases from prostate cancer.

Authors:  L C McLoughlin; F O'Kelly; C O'Brien; M Sheikh; J Feeney; W Torreggiani; J A Thornhill
Journal:  Ir J Med Sci       Date:  2014-11-14       Impact factor: 1.568

2.  [Surgical treatment of skeletal metastases].

Authors:  T Gösling; M Becker-Schiebe
Journal:  Unfallchirurg       Date:  2015-04       Impact factor: 1.000

Review 3.  PET/MR in prostate cancer: technical aspects and potential diagnostic value.

Authors:  Michael Souvatzoglou; Matthias Eiber; Axel Martinez-Moeller; Sebastian Fürst; Konstantin Holzapfel; Tobias Maurer; Sibylle Ziegler; Stephan Nekolla; Markus Schwaiger; Ambros J Beer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-24       Impact factor: 9.236

Review 4.  Imaging of distant metastases of prostate cancer.

Authors:  Filippo Pesapane; Marcin Czarniecki; Matteo Basilio Suter; Baris Turkbey; Geert Villeirs
Journal:  Med Oncol       Date:  2018-09-14       Impact factor: 3.064

Review 5.  Unmet needs in the prediction and detection of metastases in prostate cancer.

Authors:  Oliver Sartor; Mario Eisenberger; Michael W Kattan; Bertrand Tombal; Frederic Lecouvet
Journal:  Oncologist       Date:  2013-05-06

6.  Detection and evaluation of normal and malignant cells using laser-induced fluorescence spectroscopy.

Authors:  Mohamad E Khosroshahi; Mahya Rahmani
Journal:  J Fluoresc       Date:  2011-09-08       Impact factor: 2.217

Review 7.  Diagnosis of bone metastases: a meta-analysis comparing ¹⁸FDG PET, CT, MRI and bone scintigraphy.

Authors:  Hui-Lin Yang; Tao Liu; Xi-Ming Wang; Yong Xu; Sheng-Ming Deng
Journal:  Eur Radiol       Date:  2011-09-02       Impact factor: 5.315

Review 8.  Whole-body diffusion-weighted and proton imaging: a review of this emerging technology for monitoring metastatic cancer.

Authors:  Michael A Jacobs; Li Pan; Katarzyna J Macura
Journal:  Semin Roentgenol       Date:  2009-04       Impact factor: 0.800

9.  A prospective study of bone tumor response assessment in metastatic breast cancer.

Authors:  Naoki Hayashi; Colleen M Costelloe; Tsuyoshi Hamaoka; Caimiao Wei; Naoki Niikura; Richard L Theriault; Gabriel N Hortobagyi; John E Madewell; Naoto T Ueno
Journal:  Clin Breast Cancer       Date:  2012-10-24       Impact factor: 3.225

10.  Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer.

Authors:  T Hamaoka; C M Costelloe; J E Madewell; P Liu; D A Berry; R Islam; R L Theriault; G N Hortobagyi; N T Ueno
Journal:  Br J Cancer       Date:  2010-01-26       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.